Pediatric primary intramedullary spinal cord glioblastoma

Robert Lober,1** Suash Sharma,1 Beverly Bell,2 Alan Free,4 Ramon Figueroa,3 Chris W. Sheils,3 Mark Lee,5** John Cowell1

Departments of 1Pathology, 2Pediatrics (Oncology), 3Neuroradiology, 4Neurosurgery, 5Radiation Oncology, and 6MCG Cancer Center, Medical College of Georgia, Augusta, GA, USA

1Currently Department of Neurosurgery, Stanford University School of Medicine, Palo Alto, CA, USA
2Currently Department of Neurosurgery, Dell Children’s Medical Center, Austin, TX, USA

Abstract

Spinal cord tumors in pediatric patients are rare, representing less than 1% of all central nervous system tumors. Two cases of pediatric primary intramedullary spinal cord glioblastoma at ages 14 and 8 years are reported. Both patients presented with rapid onset paraparesis and quadraparesis. Magnetic resonance imaging in both showed heterogeneously enhancing solitary mass lesions localized to lower cervical and upper thoracic spinal cord parenchyma. Histopathologic diagnosis was glioblastoma. Case #1 had a small cell component (primitive neuroectodermal tumor-like areas), higher Ki67, and p53 labeling indices, and a relatively stable karyotype with only minimal single copy losses involving regions: Chr8;pter-30480019, Chr16;pter-29754532, Chr16;56160245-qter on retropositive comparative genomic hybridization using formalin-fixed, paraffin-embedded samples. Case #2 had relatively bland histomorphology and negligible p53 immunoreactivity. Both underwent multimodal therapy including gross total resection, postoperative radiation and chemotherapy. However, there was no significant improvement in neurological deficits, and overall survival in both cases was 14 months. This report highlights the broad histological spectrum and poor overall survival despite multimodality therapy. The finding of relatively unique genotypic abnormalities resembling pediatric embryonal tumors in one case may highlight the value of genome-wide profiling in development of effective therapy. The differences in management with intracranial and low-grade spinal cord gliomas and current management issues are discussed.

Introduction

Spinal cord tumors are rare in children, representing less than 1% of all central nervous system (CNS) tumors.1,2 Within this small fraction, intramedullary spinal cord (ISC) tumors constitute about 35% of the spinal tumors found in children3 compared to 5% in adults.4 Low-grade gliomas such as ependymomas and astrocytomas account for the majority, with only about 1-3% being high-grade gliomas.5 A recent review of the cases of pediatric ISC-glioblastoma (GBM) reported in the last two decades is summarized in Table 1. Patients were treated with multimodality therapeutic regimens similar to their adult counterparts. The roles of maximum safe surgical resection and radiotherapy are well established in the treatment of pediatric high-grade glioma in the intracranial location, and in non-infiltrative spinal cord tumors, but not in high-grade spinal cord gliomas where recent studies discourage the use of radical surgery.6 The role of chemotherapy remains undefined.7 Based on this limited dataset, critical underlying genomic events and the determination of the optimal therapeutic approach in this rare disease are unknown.8 This report describes two cases of pediatric primary ISC-GBM. Both had gross total resection, and were treated with adjunctive chemotherapy and radiation therapy as per the Children’s Oncology Group protocol ACNS0126 for intracranial gliomas extrapolated to high-grade spinal cord gliomas.9 Results of comparative genomic hybridization in one case in whom adequate tissue and call rate was available is also provided. A review of pertinent literature aims to provide a comparative and balanced perspective.

Case #1

A 14-year-old Asian–American female presented with a six-month history of lower extremity dysesthesias, which progressed to lower extremity weakness and gait difficulties several days before presentation. Magnetic resonance imaging (MRI) of the brain and spine performed at an outside hospital (images currently unavailable) revealed an intramedullary enhancing mass extending from the level of the sixth cervical (C6) to fifth thoracic (T5) vertebra. She underwent cervical and thoracic laminectomies with gross total resection of the tumor. The histopathologic diagnosis was GBM (Figure 1A-E). Postoperatively, the patient had paraplegia and an upper extremity strength of 1/5, which improved to 4/5 within two weeks with steroids and physical therapy. During rehabilitation, she required treatment for wound infection and dehiscence. She began the Children’s Oncology Group protocol ACNS0126 with radiation therapy and chemotherapy in the treatment of high-grade glioma.10 She received 5400 cGy to her cervical and thoracic spine in 28 evenly divided fractions. On the fifth day of radiation therapy, she began oral temozolomide at 50 mg/m2/day for six weeks, followed by a four-week rest. Maintenance therapy consisted of 10 courses of 28-day cycles of oral temozolomide 200 mg/m2/day for five days, followed by 23 days of rest. During this therapy, she reported subjective improvement in leg strength, but remained wheelchair-bound.

MRI of the spine six months after resection showed progression of the tumor, extending from the level of C5 to T3. Post-radiotherapy changes were seen throughout the spinal axis. Nine months after resection, MRI of the spine showed a stable lesion, with cord expansion and myelomalacia in a similar distribution. Whole-body PET imaging from the skull to the thigh was negative for metastasis or lymphadenopathy. Fourteen months after resection, the patient died while in hospice care.

Case #2

An eight-year-old African–American female presented with a three-week history of neck pain and weakness, which progressed to significant weakness in all extremities. MRI of the brain and spine revealed an intramedullary enhancing mass originating from the central portion of the spinal cord, extending from the level of C3 to T4 with significant cord expansion from C3 to T3 (Figure 2A-E). Of note, pre-
operative cerebrospinal fluid cytology was negative for malignancy. She underwent C1 to T2 laminectomies with gross total resection of the tumor and posterior osteoplastic arthrodesis. A histopathologic diagnosis of GBM was made (see Pathology section for details). Post-operatively, she was found to have sensations bilaterally, movement in both upper extremities, and some movement in the right foot. She was referred to the Rehabilitation Center, where she began treatment according to the Children’s Oncology Group protocol ACNS0126. She received fractionated radiation therapy to her cervical and thoracic spine, and oral temozolomide therapy as described for case #1. One year after resection, MRI of the spine demonstrated that her tumor had not progressed. She had developed an acute angle kyphotic deformity, most pronounced at C4 to C5, with spinal cord compression. There was no subsequent improvement in her neurological deficits.

Fourteen months after resection, she presented to the Emergency Department and required intubation for respiratory failure and treatment for severe bronchopneumonia. MRI of the brain and spinal cord showed interval development of edema and contrast enhancement from the lower medulla to the level of T2, consistent with recurrence. On her fifth hospital day, she became unresponsive to stimuli and had absent corneal reflexes. The patient died the next day, 14 months after tumor resection.

### Pathology

Histological examination of the resected masses in both cases revealed high-grade infiltrating astrocytic neoplasms with necrosis and microvascular proliferation. No obvious pseudopalisading around the areas of necrosis were seen in either case. Individual neoplastic cells demonstrated significant nuclear pleomorphism, anaplasia and high mitotic activity with scattered apoptotic bodies (Figures 1A and B; 2F-J, respectively), including small cells focally resembling a primitive neuroectodermal tumor (PNET) but with microvascular proliferation (Figure 1B). A diagnosis of GBM, WHO grade IV, was rendered. Diffuse immunopositivity for glial fibrillary acidic protein (GFAP) supported the diagnoses in both cases (Figures 1C and 2K).

In case #1, there was a small cell component and more conspicuous anaplasia as compared to case #2. The neoplastic cells in case #1 showed a high Ki67 (MIB1) immunohistochemical nuclear labeling index of up to about 70%, and a high p53 labeling index of up to about 30% (Ki67 stain; 200X). (E) The tumor shows a high p53 immunohistochemical nuclear labeling index of up to about 70% (p53 stain; 200X).

Figure 1. Case #1. (A) Densely cellular neoplasm, with hyperchromatic and pleomorphic astrocytic cells in a well-formed fibrillary background meshwork, with focal necrosis (H&E stain; 100X magnification). (B) Densely cellular infiltrating portion of the neoplasm, with markedly hyperchromatic and pleomorphic overlapping astrocytic cells in a rather sparse fibrillary background with focal necrosis, including small cells focally resembling a primitive neuroectodermal tumor but with microvascular proliferation (H&E stain; 200X). (C) The tumor shows diffuse glial fibrillary acidic protein (GFAP) positivity with dense fibrillary network in portions (GFAP stain; 400X). (D) The tumor shows a high Ki67 (MIB1) immunohistochemical nuclear labeling index of up to about 30% (Ki67 stain; 200X). (E) The tumor shows a high p53 immunohistochemical nuclear labeling index of up to about 70% (p53 stain; 200X).

Each sample from case #1, were previously analyzed using array comparative genomic hybridization (aCGH). These analyses revealed a relatively stable karyotype with only minimal single copy losses involving regions: Chr8:30480019, Chr16: 56160245-88668979, and Chr19:32848902-30480019, Chr16;pter-29754532, Chr16; 56160245-88668979, and Chr19:32848902-
Discussion

The ISC is the location of only one third of 1% of pediatric CNS tumors.15 Of these, high-grade gliomas such as the two ISC-GBM cases reported here constitute only about 1-3%, far outnumbered by the low-grade gliomas and ependymomas.6 These are rare tumors, and even with many recent advances in preoperative imaging, micro-neurosurgery and radiation/chemotherapy protocols,13 the overall survival after multimodality therapy has been comparable to that in adults.14,15 A review of cases of pediatric ISC-GBM reported in the last two decades is summarized in Table 1.

Clinical features

The clinical presentation of any ISC tumor relates to the region of the spinal cord involved.2,6 Up to 60% of pediatric ISC astrocytomas can show holocord presentation,17 which is unusual in adults. The most common symptoms in pediatric ISC tumors are pain (42%), motor regression (36%), gait abnormalities (27%), torticollis (27%), and progressive kyphoscoliosis (24%).1 The cases reported here presented with non-specific neck pain or lower extremity dysesthesias, which soon worsened to progressive weakness and gait difficulties. In a recent study, preoperative symptom duration of more than 180 days was associated with improved survival in infiltrative spinal cord astrocytomas.4

Radiological features

Most cases of ISC-GBM showed MRI imaging characteristics similar to intracranial GBM. Occasional atypical features included an

| Table 1. Main clinicopathologic data in the reported pediatric cases of histopathologically confirmed intramedullary glioblastomas of the spinal cord. |
|---|---|---|---|---|---|---|---|---|---|
| Case | Ref. | Age/sex | Site | Surgery | RT | CTX | Rec | F/U (months) | Outcome |
| 1 | 31 | 4 M | Holocord | Partial | None | + | + | 37 | DOT |
| 2 | 31 | 13 F | Cervical | Total | + | + | + (CSF) | 15 | DOD |
| 3 | 31 | 15 M | Cervical | Partial | - | + | + (CSF) | 8 | DOD |
| 4 | 20 | 16 F | T12-L1 | Subtotal | + | NA | + (CSF) | 6 | DOD |
| 5 | 20 | 14 M | T12-L1 | Subtotal | + | ? | + (CSF) | 4 | DOD |
| 6 | 7 | <3 | NA | Subtotal | + | + | + | 23 | Alive |
| 7 | 38 | 12 | C1-C7 | Partial | NA | NA | NA | NA | Alive |
| 8 | 39 | 20 M | T12-L1 | Subtotal | + | - | + (CSF) | 11 | DOD |
| 9 | 3 | 1.8 F | C7-T7 | Total | 55 Gy | - | + | 14 | DOD |
| 10 | 3 | 1.4 M | C7-T2 | Subtotal | 38 Gy | + | + | 13 | DOD |
| 11 | 3 | 1.0 M | C3-T7 | Biopsy | 48 Gy | + | + | 24 | DOD |
| 12 | 13 | 0.7 M | C5-L1 | Total | 40 Gy | NA | - | 144 | Alive |
| 13 | 13 | 17.9 M | T9-L1 | Subtotal | None | NA | - | 3 | DOD |
| 14 | 16 | 19 F | NA | NA | NA | NA | NA | NA | 9 | DOD |
| 15 | 16 | 18 F | C7-T7 | Total | + | NA | NA | 21 | DOD |
| 16 | 16 | 3 M | T7 | Biopsy | + | + | + (CSF) | 13 | DOD |
| 17 | 16 | 14 M | C2-C7 | Subtotal | + | + | NA | 9 | DOD |
| 18 | 16 | 19 M | C4-C6 | Subtotal | + | NA | NA | 12 | DOD |
| 19 | 17 | 14 M | T12-L1 | Total | NA | NA | + (CSF) | 9 | NA |
| 20 | 5 | 12 M | C1-T1 | Subtotal | CSI 48.6 | NA | + (CSF) | 7 | NA |
| 21 | 5 | 9 F | C1-T1 | Subtotal | Focal 38 | NA | + (CSF) | 1 | NA |
| 22 | 5 | 23 F | C5-5 | Total | Focal 50.4 | NA | Local | 24 | NA |
| 23 | 5 | 11 F | C1-T1 | Total | Focal 50 | NA | - | 150 | Stable |
| 24 | 5 | 5 F | C3-T2 | Biopsy | CSI 38, Focal 48 | NA | - | 239 | Stable |
| 25 | 5 | 10 M | C1,2,T6-8 | Subtotal | CSI 48.4, focal 66 | NA | + (CSF) | 2 | NA |
| 26 | 5 | 10 M | C2-T6 | Subtotal | Focal 54 | NA | Local | 72 | NA |
| 27 | 5 | 11 F | C2-C7 | Subtotal | Focal 54 | NA | + (CSF) | 1 | NA |
| 28 | 5 | 15 F | C7-T7 | Total | Focal 55 | NA | Local | 10 | NA |
| 29 | 5 | 14 M | C7-T2 | Subtotal | CSI 38.5 | NA | Local | 4 | NA |
| 30 | 5 | 10 F | C3-T7 | Biopsy | Focal 48 | NA | + (CSF) | 14 | NA |
| 31 | 5 | 17 M | C1-5 | Subtotal | Focal 54 | NA | Local | 4 | NA |
| 32 | 5 | 13 F | C1-T1 | Biopsy | Focal 54 | NA | + (CSF) | 1 | NA |
| 33 | 5 | 3 M | C3-T8 | Subtotal | CSI 34.2, focal 55.2 | NA | - | 88 | Stable |
| 34 | 5 | 15 F | T10-11 | Subtotal | CSI 39.6, focal 51.3 | NA | + (CSF) | 1 | NA |
| 35 | 5 | 12 M | T12 | Subtotal | Focal 54 | NA | + (CSF) | 4 | NA |
| 36 | 5 | 9 F | T2-7 | Subtotal | CSI 36, focal 54 | NA | - | 10 | Stable |
| 37 | 8 | 14 F | C6-T5 | Total | + | + | + | 14 | DOD |
| 38 | 8 | 14 F | C3-T4 | Subtotal | + | + | + | 14 | DOD |

RT, radiation therapy; CTX, chemotherapy; Rec, recurrence; M, male; F, female; NA, not available; CSI, craniospinal irradiation; CSF, cerebrospinal fluid; DOT, died of toxicity; DOD, died of disease.
Case Report

Figure 2. Case #2. (A) T1 weighted sagittal magnetic resonance images without contrast show an intramedullary hypointense mass lesion present within the central portion of the cervical spinal cord from C3 to T3 levels, producing expansion. (B) T1 weighted sagittal MR images with contrast show an intramedullary enhancing mass lesion present within the central portion of the cervical spinal cord, originating from the region of the central canal, producing expansion. The spinal cord measures 13 mm at the greatest AP diameter. The mass shows rim enhancement with central cystic changes and is surrounded by normal-appearing spinal cord. This mass extends from the level of the obex inferiorly to the T4 vertebral body. The maximum bulk of the mass is present from C3 to T3 levels. This mass produces remodeling of the posterior vertebral bodies most notably at C4 to C7. (C) T2 weighted sagittal MRI showing an expansile intramedullary mass lesion present within the cervical spinal cord. (D) Post-contrast T1 weighted axial MRI showing an enhancing expansile intramedullary mass lesion present within the central portion of the spinal cord. (E) Post-contrast T1 weighted axial MRI showing a ring-enhancing expansile intramedullary mass lesion present within the central portion of the spinal cord. (F) Moderate to focal densely cellular neoplasm with moderately hyperchromatic and pleomorphic loosely arranged astrocytic cells, with focal marked microvascular proliferation (H&E stain; 200X). (G) Areas of necrosis within the astrocytic neoplasm. No pseudopalisading is appreciated (H&E stain; 100X). (H) Moderate to focal densely cellular neoplasm with moderately hyperchromatic and pleomorphic astrocytic cells, with more than one mitosis in one high-power field, and with focal moderate microvascular proliferation (H&E stain; 400X). (J) Moderately hyperchromatic and pleomorphic astrocytic cells, with more than one mitosis in one high-power field (H&E stain; 400X). (K) Irregular infiltration of diffusely immunopositive neoplastic astrocytic cells, with negative images of hyperplastic vessels (GFAP stain; 100X). (L) The tumor shows a high Ki67 (MIB1) immunohistochemical nuclear labeling index of up to about 20% (Ki67 stain; 200X). (M) The tumor shows a negligible p53 immunohistochemical nuclear labeling index of less than 5% (p53 stain; 200X).
expansive ISC mass, with signal intensity compatible with either low-grade astrocytoma or ependymoma on T1 weighted images.7 Others were exophytic with features suggesting meningioma.6 Both current cases showed enhancing ISC masses on MRI that were worrisome for high-grade glioma.

Surgical resection

In low-grade non-infiltrative tumors such as ependymomas or pilocytic astrocytomas, radical excision using recent microsurgical advances1 before the onset of significant disability is the standard of care and often results in improved risk-benefit ratio, and a good long-term prognosis.18 However, in high-grade tumors, the value of surgery is less clear. In pediatric intracranial malignant astrocytomas, significant improvement in progression-free survival (PFS) has been reported following radical tumor resection.19 The data in pediatric ISC tumors are debatable. In some studies, gross total or subtotal resection could be achieved in a majority of patients with minimal short-term morbidity.3,5,32 Radio-cordectomy and cordotomy was also associated with improved survival.4 However, radical tumor resection of high-grade spinal cord gliomas has not been shown to alter the relentless clinical deterioration and short overall survival of this devastating tumor, and instead carries the risk of permanent neurological sequelae and impairment of the quality of the patients’ brief remaining lives.3,8 The current recommendation in high-grade ISC tumors is diagnostic biopsy followed by postoperative radiation therapy,31 and to reserve extensive surgery for anaplastic astrocytomas9 and palliation in patients in whom RT is not well-tolerated or contraindicated.14 The rationale behind radical surgery in select cases of high-grade spinal cord gliomas includes obtaining adequate tissue for diagnosis, cytoreductive tumor debulking, and helping relieve pain.20 In our study, although both patients had a similar poor outcome, the histological diversity, with a small cell component resembling PNET in case #1, lack of overt high-grade cytology on frozen sections in case #2, and the resulting need to establish correct diagnosis along with debulking justify maximal safe resection.

Pathological features

Histological type and grade are the most important prognostic factors in ISC glioma.1,3,6 The histopathological features of ISC-GBM are identical to intracranial tumors in adults,6 except for possibly increased leptomeningeal involvement owing to proximity to the subarachnoid space.36 The current cases showed a wide histological spectrum ranging from PNET-like areas in case #1 to relatively bland areas in case #2. The predictive value of MIB-1 labeling index is unclear,3,14 with no statistically-significant difference in outcome between cases with MIB-1 labeling index above and below 5%.14 In our report, both cases were associated with high Ki67 labeling indices. Pediatric high-grade gliomas in children over three years of age have been found to have a higher frequency of TP53 mutations and overexpression (40%), indicating potential existence of two different molecular pathways of tumorigenesis.2,25 The relationship of p53 overexpression to progression to GBM,12,13 worse progression-free survival,12 and brain metastases in spinal GBM10 found in some studies, were not reproduced in other studies.16 In our two cases, p53 immunohistochemical labeling indices were different (70% in case #1 vs. 5% in case #2), yet they had similar overall survival of 14 months. Adult GBM shows a characteristic range of cytogenetic abnormalities that occur at high frequency in subsets of tumors. Loss of chromosome 10, deletion of the p16 gene in 9p21 (often homozygous) amplification of the EGFR locus, and gain of chromosome 7 are among the most common events26 seen in these tumors. None of these cytogenetic abnormalities, or any others less frequent but typical of adult GBM, were seen in case #1 described in this report. Our findings correlate with pediatric glioblastomas in general41 and are similar to other recent reports on pediatric GBM.26 Although losses involving 8p, 16p, and 16q are reported occasionally in adult GBM, they are not frequent in pediatric GBM. Losses involving the long arm of chromosome 19 are also infrequent and more typically found in anaplastic oligodendroglioma.7 In fact, losses involving 8p and 16q are far more typical of medulloblastomas.26 From a genetic standpoint, therefore, the pediatric GBM described here is more typical of pediatric brain tumors than adult GBM.

Radiation therapy

Radiation therapy (RT) provides temporary clinical and radiographic improvement, and prolongs survival in high-grade gliomas for some pediatric patients, yet it is rarely curative.3,4 An exception is infants and children under three years of age in whom adjuvant treatments are reserved for tumor recurrence.2,3 The risk of post-radiation growth suppression or second malignancy following treatment of non-infiltrative spinal cord tumors such as ependymomas or pilocytic astrocytomas is not an issue in high-grade gliomas owing to their short life span. In current treatment protocols, adult patients with high-grade gliomas receive 5,400-6,000 cGy local radiation to the brain tumor bed, with a peri-tumoral margin to account for tumor infiltration, in daily fractions of 180-200 cGy.7 The spinal cord is less tolerant of radiation, so the radiation dose was restricted to 5040 cGy in both our patients, to avoid the risk of transverse myelitis. As RT is now considered to be the standard management in infiltrative high-grade ISC astrocytomas,3 and many such patients present with near paraplegia, higher doses up to 5940 cGy have been reported in the literature. However, when used in conjunction with chemotherapy or potential radiosensitizer (TMZ), a lower dose of radiotherapy is reasonable. In a recent study, patients with infiltrative spinal cord astrocytomas who received postoperative RT to a dose of >3500 cGy had a significantly better survival than those with a lesser dose or no RT.26 Considering the wide range of radiation dose reported (Table 1), the dose is best individualized.

Chemotherapy

There is no proven effective chemotherapy for high-grade gliomas in children. Yet, most children, with high-grade gliomas receive chemotherapy in addition to surgery and radiation therapy.2,3,32 There are reports of improved survival in pediatric high-grade ISC tumors by addition of chemotherapy.12,32 The optimal timing of chemotherapy and radiation (preoperative vs. postoperative) is debated. While preoperative chemotherapy is considered to provide optimum treatment to undisturbed tumor microvasculature,32 postoperative chemotherapy may be more efficacious owing to disruption in the blood-brain barrier.29 Drugs that have been used in clinical trials in the Children’s Oncology Group studies include temozolomide, anti-angiogenesis agents, immunotoxins, and other maturational and differentiating agents. In this report, both patients presented with a rapid decline in function, necessitating urgent surgical intervention prior to other modalities.

Outcomes

Patients with infiltrative astrocytoma of the spinal cord had uniformly poor survival36 regardless of age.1 Cases with ISC-GBM invariably progress despite aggressive chemotherapy and radiation therapy,12,32 and long-term functional outcomes have been poor.1,3,33,34 For pediatric intracranial malignant gliomas, the median survival with conventional-dose chemotherapy and radiation therapy is 11-24 months, with an overall survival of 5-20% at five years,3,31 with a worse outcome for GBM than grade III gliomas.29,35 Yet, most publications have not shown a survival advantage in pediatric intramedullary high-grade gliomas with multimodality therapy.7,36 Owing to high histological grade, lack of adequate cleavage plane between tumor and spinal tissue, and easy access to CSF,36 Median overall survival has been reported to be shorter with neuraxis dissemination than local failure alone.7 The reportedly higher leptomeningeal involvement in spinal GBM...
(39%) compared to cerebral GBM (27%) indicates CSF spread as a more important cause of death than direct brainstem involvement, thereby necessitating regular MRI and CSF cytology. In our cases, preoperative CSF cytology did not show neoplastic cells. The patients died from complications of respiratory failure, likely a result of MRI-detected local tumor recurrence and brainstem involvement.

Conclusions

The spinal cord is a rare site of pediatric GBM, which has a poor overall survival despite multimodality therapy. The novel aspects of the study include diverse histological spectrum, treatment with Children’s Oncology Group protocol ACNS0126, and relatively unique CGH treatment with Children’s Oncology Group study include diverse histological spectrum, multimodality therapy. The novel aspects of the management of effective treatment strategies. The cases presented here highlights the potential role of radiotherapy in the management of high-grade spinal cord astrocytoma: childhood: a report of the Children’s Oncology Group. Cancer 2007;110:1542-50.

References

1. Epstein FJ. Pediatric Neurosurgery. Philadelphia: W.B. Saunders, 1994.
2. Helseth A, Mark SJ. Primary intraspinal neoplasms in Norway, 1955 to 1986. A population-based survey of 467 patients. J Neurosurg 1989;71:842-5.
3. Merchant TE, Nguyen D, Thompson SJ, et al. High-grade pediatric spinal cord tumors. Pediatr Neurosurg 1999;30:1-5.
4. Minehan KJ, Brown PD, Scheithauer BW, et al. Prognosis and treatment of spinal cord astrocytoma. Int J Radiat Oncol Biol Phys 2009;73:727-33.
5. Tendulkar RD, Panandiker AS, Wu S, et al. Irradiation of pediatric high-grade spinal cord tumors. Int J Radiat Oncol Biol Phys 2010. [Epub ahead of print]
6. Ciappetta P, Salvari M, Capoccia G, et al. Spinal glioblastomas: report of seven cases and review of the literature. Neurosurgery 1991;28:302-6.
7. Constantini S, Houten J, Miller DC, et al. Intramedullary spinal cord tumors in children under the age of 3 years. J Neurosurg 1996;85:1036-43.
8. Shirato H, Kamada T, Hida K, et al. The role of radiotherapy in the management of spinal cord glioma. Int J Radiat Oncol Biol Phys 1995;33:323-8.
9. Gottardo NG, Gajjar A. Chemotherapy for malignant brain tumors of childhood. J Child Neurol 2008;23:1149-59.
10. Nicholson HS, Krettschmar CS, Kralio M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children’s Oncology Group. Cancer 2007;110:1542-50.
11. Sharma S, Free A, Mei Y, et al. Distinct molecular signatures in Pediatric infratentorial glioblastomas defined by aCGH. Exp Mol Pathol 2010. [Epub ahead of print].
12. Lo KC, Rossi MR, LaDuca J, et al. Candidate glioblastoma development gene identification using concordance between copy number abnormalities and gene expression level changes. Genes Chromosomes Cancer 2007;46:875-94.
13. Przybyski GJ, Albright AL, Martinez AJ. Spinal cord astrocytomas: long-term results comparing treatments in children. Childs Nerv Syst 1997;13:375-82.
14. Iwata K, Nakagawa H, Hashizume Y. Significance of MIB-1, PCNA indices, and p53 protein over-expression in intramedullary tumors of the spinal cord. Noshuyo Byori 1996;13:73-8.
15. Strik HM, Effenberger O, Schäfer O, et al. A case of spinal glioblastoma multiforme: immunohistochemical study and review of the literature. J Neurooncol 2000;50:239-43.
16. Santi M, Mena H, Wong K, et al. Spinal cord malignant astrocytomas. Clinicopathologic features in 36 cases. Cancer 2003;98:554-61.
17. Stecco A, Quirico C, Giampietro A, et al. Glioblastoma multiforme of the conus medullaris in a child: description of a case and literature review. AJNR Am J Neuroradiol 2005;26:2157-60.
18. McGirt MJ, Chaichana KL, Atiba A, et al. Resection of intramedullary spinal cord tumors in children: assessment of long-term motor and sensory deficits. J Neurosurg Pediatr 2008;1:63-7.
19. Wisoff JH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 1998;89:52-9.
20. Cohen AR, Wisoff JH, Allen JC, Epstein F. Malignant astrocytomas of the spinal cord. J Neurosurg 1989;70:50-4.
21. Pollack IF, Finkelstein SD, Burnham J, et al. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res 2001;61:7404-7.
22. Pollack IF. The role of surgery in pediatric gliomas. J Neurooncol 1999;42:271-88.
23. Sarkar C, Ratte ALM, Sharma MC, Mehta VS. Recurrent astrocytic tumours—a study of p53 immunoactivity and malignant progression. Br J Neurosurg 2002;16:335-42.
24. Pollack IF, Finkelstein SD, Woods J, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 2002;346:420-7.
25. Lo KC, Bailey D, Burkhardt T, et al. Comprehensive analysis of loss of heterozygosity events in glioblastoma using the 100K SNP mapping arrays and comparison with copy number abnormalities defined by BAC array comparative genomic hybridization. Genes Chromosomes Cancer 2008;47:221-37.
26. Suri V, Das P, Pathak P, et al. Pediatric glioblastomas: A histopathological and molecular genetic study. Neuro Oncol 2009;11:274-80.
27. Rossi MR, Galie D, Luduca J, et al. Identification of consistent novel submegabase deletions in low-grade oligodendrogliomas using array-based comparative genomic hybridization. Genes Chromosomes Cancer 2005;44:85-96.
28. Lo KC, Rossi MR, Eberhart CG, Cowell JK. Genome wide copy number abnormalities in pediatric medulloblastomas as assessed by array comparative genome hybridization. Brain Pathol 2007;17:282-96.
29. Reddy AT, Wellons JC 3rd. Pediatric high-grade gliomas. Cancer J 2003;9:107-12.
30. Massimino M, Gandola L, Lukesch R, et al. Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro Oncol 2005;7:41-8.
31. Allen JC, Aviner S, Yates AJ, et al. Treatment of high-grade spinal cord astrocytoma of childhood with “8-in-1” chemotherapy and radiotherapy: a pilot study of CCG-945. Children’s Cancer Group. J Neurosurg 1998;88:215-20.
32. Sposto R, Ertel JJ, Jenkins RD, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Children’s Cancer Study Group. J Neurosurg 1989;71:165-77.
33. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998;4:655-7.
34. Rothbauer KF. Neurosurgical management of intramedullary spinal cord tumors in children. Pediatr Neurosurg 2007;43:222-35.
35. Nakamura M, Ishii K, Watanabe K, et al. Surgical treatment of intramedullary spinal cord tumors: prognosis and complications. Spinal Cord 2008;46:282-6.
36. Kreth FW, Berlis A, Spiropoulou V, et al. The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer 1999;86:2117-23.
37. Goh KY, Velasquez I, Epstein FJ. Pediatric intramedullary spinal cord tumors: is surgery alone enough? Pediatr Neurosurg 1997;27:34-9.
38. Klepstad P, Borchgrevink P, Hval B, et al. Long-term treatment with ketamine in a 12-year-old girl with severe neuropathic pain caused by a cervical spinal tumor. J Pediatr Hematol Oncol 2001;23:616-9.
39. Medhkour A, Chan M. Extremely rare glioblastoma multiforme of the conus medullaris with holocord and brain stem metastases, leading to cranial nerve deficit and respiratory failure: a case report and review of the literature. Surg Neurol 2005;63:576-82; discussion 582-3.